4 minute read
Aug. 26, 2022

Compound 3f: an Oral Factor XIa (FXIa) Inhibitor for Thromboembolic Diseases

compound 3f

oral Factor XIa inhibitor IV efficacy in rabbit AV shunt model from literature starting point and SBDD J. Med. Chem., July 21, 2022 Janssen Research & Development, L.L.C., Spring House, PA

drughunter.com
Drug Hunter Team

“ Compound 3f ” (Janssen) is an oral Factor XIa (FXIa) inhibitor being developed for thromboembolic diseases. The suitability of FXIa as a target in the development of anticoagulation agents stems from observations that the coagulation factor contributes significantly to pathological blood clotting (thrombosis) but plays a negligible [...]

Loading...

twitterlinkedinemail

Other molecules you may be interested in